MarketLens

What Makes Elisrasib's ASCO 2026 Data So Significant

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Did D3 Bio Present at ASCO 2026 for Elisrasib

3 months ago

What Makes Akeso's ASCO 2026 Plenary Session So Crucial

3 months ago

What Makes Roche's $700 Million Bet on Nurix So Significant

3 months ago

What Did Ascentage Pharma Present at ASCO 2026

3 months ago

NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger

NeOnc Technologies' Phase 2a readout for NEO100 in recurrent brain cancer showed a meaningful signal, shifting focus to whether results can support a registration path. The company's next milestone hi...

NTHI

Stock News•3 weeks ago

ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case

ArriVent BioPharma's Firmonertinib readout moved to H2 2026, likely reflecting slower event accumulation and longer progression-free survival. The drug remains the core value driver, with pipeline exp...

ARR

Stock News•2 months ago

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Erasca's ERAS-0015 showed 57% uORR in 2L KRAS G12X pancreatic cancer at 32 mg QD RDE, with 100% median relative dose intensity. Company plans registration-enabling lung cancer trial in H1 2027 and Pha...

ERAS